Y. Andersson, Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo, British Journal of Cancer, vol.257, issue.8, pp.1307-1315, 2009.
DOI : 10.1111/j.1600-0625.2007.00555.x

K. Risberg, Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma, PLoS ONE, vol.115, issue.9, p.24012, 2011.
DOI : 10.1371/journal.pone.0024012.s005

I. Pastan, Immunotoxins containing Pseudomonas exotoxin A: a short history, Cancer Immunol. Immunother, vol.52, pp.338-341, 2003.

S. Song, Preparation and characterization of fusion protein truncated Pseudomonas Exotoxin A (PE38KDEL) in Escherichia coli, Protein Expression and Purification, vol.44, issue.1, pp.52-57, 2005.
DOI : 10.1016/j.pep.2005.04.004

R. J. Kreitman, Immunotoxins for targeted cancer therapy, The AAPS Journal, vol.8, issue.3, pp.532-551, 2006.
DOI : 10.1208/aapsj080363

L. M. Ellis and D. J. Hicklin, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nature Reviews Cancer, vol.119, issue.8, pp.579-591, 2008.
DOI : 10.1038/nrc2403

J. Folkman, Angiogenesis: an organizing principle for drug discovery?, Nature Reviews Drug Discovery, vol.57, issue.5, pp.273-286, 2007.
DOI : 10.1038/nrd2115

M. Behdani, Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor, Molecular Immunology, vol.50, issue.1-2, pp.35-41, 2012.
DOI : 10.1016/j.molimm.2011.11.013
URL : https://hal.archives-ouvertes.fr/pasteur-00820543

M. V. Backer and J. M. Backer, Targeting Endothelial Cells Overexpressing VEGFR-2:?? Selective Toxicity of Shiga-like Toxin???VEGF Fusion Proteins, Bioconjugate Chemistry, vol.12, issue.6, pp.1066-1073, 2001.
DOI : 10.1021/bc015534j

T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays, Journal of Immunological Methods, vol.65, issue.1-2, pp.55-63, 1983.
DOI : 10.1016/0022-1759(83)90303-4

A. Bikfalvi, Angiogenesis and invasion in cancer, Handb. Clin. Neurol, vol.104, pp.35-43, 2012.
DOI : 10.1016/B978-0-444-52138-5.00003-7

F. Fan, Targeting the Tumor Microenvironment: Focus on Angiogenesis, Journal of Oncology, vol.4, issue.6, p.281261, 2012.
DOI : 10.1126/science.1125950

P. B. Vermeulen, Angiogenesis, lymphangiogenesis, growth pattern, and tumor emboli in inflammatory breast cancer, Cancer, vol.122, issue.S11, pp.2748-2754, 2010.
DOI : 10.1002/cncr.25169

R. J. Tomanek, VEGF Family Members Regulate Myocardial Tubulogenesis and Coronary Artery Formation in the Embryo, Circulation Research, vol.98, issue.7, pp.947-953, 2006.
DOI : 10.1161/01.RES.0000216974.75994.da

N. Ferrara, The role of VEGF in the regulation of physiological and pathological angiogenesis, EXS, vol.94, pp.209-231, 2005.
DOI : 10.1007/3-7643-7311-3_15

S. R. Silva, VEGFR-2 expression in carcinoid cancer cells and its role in tumor growth and metastasis, International Journal of Cancer, vol.9, issue.5, pp.1045-1056, 2011.
DOI : 10.1002/ijc.25441

K. R. Molhoek, VEGFR-2 expression in human melanoma: Revised assessment, International Journal of Cancer, vol.356, issue.2, pp.2807-2815, 2011.
DOI : 10.1002/ijc.25963

A. A. Lushnikova, VEGFR-2 expression in tumor tissue of breast cancer patients, Doklady Biological Sciences, vol.434, issue.1, pp.363-367, 2010.
DOI : 10.1134/S0012496610050194

M. V. Backera, Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2, Journal of Controlled Release, vol.74, issue.1-3, pp.349-355, 2001.
DOI : 10.1016/S0168-3659(01)00346-7

N. Arora, Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells, Cancer Res, vol.59, pp.183-188, 1999.

C. Hu, Investigation of a plasmid containing a novel immunotoxin VEGF165-PE38 gene for antiangiogenic therapy in a malignant glioma model, International Journal of Cancer, vol.1, issue.9, pp.2222-2229, 2010.
DOI : 10.1002/ijc.25217

R. J. Kreitman, Phase I Trial of Recombinant Immunotoxin Anti-Tac(Fv)-PE38 (LMB-2) in Patients With Hematologic Malignancies, Journal of Clinical Oncology, vol.18, issue.8, pp.1622-1636, 2000.
DOI : 10.1200/JCO.2000.18.8.1622

R. J. Kreitman, Phase II Trial of Recombinant Immunotoxin RFB4(dsFv)-PE38 (BL22) in Patients With Hairy Cell Leukemia, Journal of Clinical Oncology, vol.27, issue.18, pp.2983-2990, 2009.
DOI : 10.1200/JCO.2008.20.2630

L. H. Pai, Treatment of advanced solid tumors with immunotoxin LMB???1: An antibody linked to Pseudomonas exotoxin, Nature Medicine, vol.12, issue.3, pp.350-353, 1996.
DOI : 10.1016/0092-8674(87)90363-1

L. Garland, Phase I Trial of Intravenous IL-4 Pseudomonas Exotoxin Protein (NBI-3001) in Patients with Advanced Solid Tumors That Express the IL-4 Receptor, Journal of Immunotherapy, vol.28, issue.4, pp.376-381, 2005.
DOI : 10.1097/01.cji.0000162782.86008.mL

I. F. Parney, Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13???PE38QQR for recurrent malignant glioma, Journal of Neurosurgery, vol.102, issue.2, pp.267-275, 2005.
DOI : 10.3171/jns.2005.102.2.0267